Please use this identifier to cite or link to this item:
Title: Management of hydroxyurea resistant or intolerant polycythemia vera.
Epworth Authors: Raman, Indu
Prince, Miles
Yannakou, Costas
Other Authors: Pasricha, Sant-Rayn
Keywords: PEGylated interferon alpha
Polycythemia vera
Hydroxyurea resistance/intolerance
Cytoreductive therapy
European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP)
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: 5-May-2021
Publisher: Taylor & Francis Online
Citation: Leuk Lymphoma. 2021 Oct;62(10):2310-2319.
Abstract: Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy are at the cornerstone of management. First line cytoreductive therapy in high-risk patients is hydroxyurea; however, its use is associated with toxicities and resistance in a significant proportion of patients. In a disease with a long overall survival with appropriate treatment, it is imperative that other treatment options do not accelerate the risk of progression to acute leukemia. The following review will appraise the evidence of interferon, ruxolitinib, and other agents in management of hydroxyurea resistant or intolerant polycythemia vera.
DOI: 10.1080/10428194.2021.1901092
ISSN: 1042-8194
Journal Title: Leukemia & Lymphoma
Type: Journal Article
Affiliated Organisations: Walter and Eliza Hall Institute, Melbourne, Australia
Peter MacCallum Cancer Institute, Melbourne, Australia
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.